{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR+Mutation+Positive+Advanced+Non+Small+Cell+Lung+Cancer", "query": { "condition": "EGFR Mutation Positive Advanced Non Small Cell Lung Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 27, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=EGFR+Mutation+Positive+Advanced+Non+Small+Cell+Lung+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T11:06:35.802Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05579366", "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Epithelial Ovarian Cancer", "High Grade Serous Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Endometrial Cancer", "Non-small Cell Lung Cancer", "Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)", "Mesothelioma", "Breast Adenocarcinoma", "Triple Negative Breast Cancer", "Hormone Receptor-positive/Her2 Negative Breast Cancer", "Platinum-resistant Ovarian Cancer (PROC)", "Platinum Sensitive Ovarian Cancer (PSOC)", "Primary Refractory Ovarian Cancer", "Uterine Cancer" ], "interventions": [ { "name": "Rina-S", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genmab", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 884, "start_date": "2022-12-07", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2026-07-07", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 32 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Barbara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05579366" }, { "nct_id": "NCT03175224", "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Cancer", "Renal Cancer", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "NSCLC", "Lung Cancer", "Brain Tumor", "Glioblastoma Multiforme", "EGFR Gene Mutation", "MET Amplification", "HGF", "Thyroid Cancer", "Pancreatic Cancer", "Colon Cancer", "MET Alteration", "MET Fusion", "Exon 14 Skipping" ], "interventions": [ { "name": "APL-101 Oral Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apollomics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 497, "start_date": "2017-09-27", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175224" }, { "nct_id": "NCT02451852", "title": "AZD9291 US Expanded Access Program", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "EGFR T790M Mutation Positive NSCLC" ], "interventions": [ { "name": "AZD9291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 32, "location_summary": "Anaheim, California • Beverly Hills, California • Burbank, California + 29 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02451852" }, { "nct_id": "NCT02296125", "title": "AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD9291 80 mg/40 mg + placebo", "type": "DRUG" }, { "name": "Placebo Erlotinib 150/100mg", "type": "DRUG" }, { "name": "Placebo Gefitinib 250 mg", "type": "DRUG" }, { "name": "Erlotinib 150/100 mg", "type": "DRUG" }, { "name": "Gefitinib 250 mg", "type": "DRUG" }, { "name": "Placebo AZD9291 80 mg/ 40 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 674, "start_date": "2014-12-03", "completion_date": "2025-11-20", "has_results": true, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 14, "location_summary": "Anaheim, California • Santa Rosa, California • West Hills, California + 10 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "West Hills", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02296125" }, { "nct_id": "NCT01814553", "title": "ADAM-Afatinib Diarrhea Assessment and Management", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "afatinib", "type": "DRUG" }, { "name": "loperamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2013-04", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2016-10-31", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 12, "location_summary": "Santa Rosa, California • Orlando, Florida • Port Saint Lucie, Florida + 7 more", "locations": [ { "city": "Santa Rosa", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Skokie", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01814553" }, { "nct_id": "NCT03239340", "title": "A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 154, "start_date": "2018-05-30", "completion_date": "2023-09-19", "has_results": true, "last_update_posted_date": "2024-10-21", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 3, "location_summary": "Athens, Georgia • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "Athens", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03239340" }, { "nct_id": "NCT07315113", "title": "Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EGFR Mutation Positive Non-small Cell Lung Cancer", "EGFR Mutated Non-small Cell Lung Cancer Patients" ], "interventions": [ { "name": "NXP900", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvectis Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2025-12-18", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 6, "location_summary": "Calverton, Maryland • Boston, Massachusetts • Eugene, Oregon + 3 more", "locations": [ { "city": "Calverton", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Eugene", "state": "Oregon" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07315113" }, { "nct_id": "NCT02438722", "title": "S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Recurrent Non-Small Cell Lung Carcinoma", "Stage IV Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Afatinib Dimaleate", "type": "DRUG" }, { "name": "Cetuximab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 174, "start_date": "2015-05-07", "completion_date": "2026-04-17", "has_results": true, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 638, "location_summary": "Fort Smith, Arkansas • Hot Springs, Arkansas • Jonesboro, Arkansas + 406 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02438722" }, { "nct_id": "NCT02630186", "title": "A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Rociletinib", "type": "DRUG" }, { "name": "MPDL3280A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Clovis Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2016-02-24", "completion_date": "2017-09-05", "has_results": true, "last_update_posted_date": "2019-07-05", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02630186" }, { "nct_id": "NCT02228369", "title": "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EGFR Mutation Positive Advanced Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD3759", "type": "DRUG" }, { "name": "AZD9291", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 108, "start_date": "2014-11-05", "completion_date": "2020-10-28", "has_results": false, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-07-23T11:06:35.802Z", "location_count": 2, "location_summary": "Los Angeles, California • Santa Monica, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02228369" } ] }